结直肠癌肝转移两阶段肝切除:术前化疗病理缓解与二期完成及生存相关
该回顾性研究纳入2003至2013年间67例接受两阶段肝切除的结直肠癌肝转移患者,评估术前化疗病理缓解与二期完成及生存的关系。结果显示病理缓解者二期完成率更高,中位总生存显著更长,提示病理缓解可预测两阶段肝切除的预后。
要点
- 病理缓解(TRG 1-3、mTRG 1-3、Blazer 0-1)与二期肝切除完成率独立相关。
- 病理缓解者中位总生存显著优于未缓解者(Blazer 0-1:42.9 vs 20.1个月)。
- 三药化疗与病理缓解相关,或可提高二期完成率。
核心结论
- 术前化疗的病理缓解与两阶段肝切除二期完成及更长生存相关。
研究设计与样本
- 回顾性研究,纳入2003至2013年间67例接受两阶段肝切除的结直肠癌肝转移患者。
- 其中56例因初始不可切除的结直肠癌肝转移行两阶段肝切除,32例化疗联合生物治疗。
主要发现
- 病理缓解(TRG 1-3:OR=4.01,95%CI 1.12-14.36,P=.033;mTRG 1-3:OR=3.8,95%CI 1.13-12.6,P=.03;Blazer 0-1:OR=5.45,95%CI 1.66-17.85,P=.005)与二期完成相关。
- 病理缓解者中位总生存显著更高(Blazer 0-1:42.9个月 vs Blazer 2:20.1个月,P=.018;TRG 1-3:42.9个月 vs TRG 4-5:25.1个月,P=.04)。
- 三药化疗与病理缓解相关。
关键数值与推荐
- 病理缓解定义:TRG 1-3、mTRG 1-3、Blazer 0-1;未缓解定义:TRG 4-5、mTRG 4-5、Blazer 2。
临床怎么用
- 两阶段肝切除前化疗后病理缓解可辅助识别二期完成概率高、生存更长的患者。
- 对病理未缓解者需审慎评估二期手术的获益。
局限性
- 回顾性研究,样本量较小(67例),结论需进一步验证。
- 需早期识别二期手术获益不明确的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Two-stage hepatectomy of bilobar colorectal liver metastases is widely used and shows encouraging survival results. However, the risk of dropout after the first stage remains high and is associated with poor survival. The objective of our study was to evaluate the factors associated with long-term survival based on the pathologic response to preoperative systemic chemotherapy in colorectal liver metastases patients who underwent two-stage hepatectomy. METHODS: The pathologic response to preoperative chemotherapy and its effect on second-stage completion and survival were retrospectively evaluated in 67 patients treated between 2003 and 2013. RESULTS: A total of 56 patients underwent two-stage hepatectomy for initially nonresectable colorectal liver metastases. Chemotherapy was combined with a biotherapy in 32 cases. The tumor regression grade, modified tumor regression grade, and Blazer grade were used to classify patients as responders (tumor regression grade and modified tumor regression grade 1-3, Blazer 0-1) or nonresponders (tumor regression grade and modified tumor regression grade 4-5, Blazer 2) after the first stage. Tumor response in the three classifications was associated with second-stage completion (tumor regression grade 1-3: OR = 4.01, 95% CI: 1.12-14.36, P = .033; modified tumor regression grade 1-3: OR = 3.8, 95% CI: 1.13-12.6, P = .03; Blazer 0-1: OR = 5.45, 95% CI: 1.66-17.85, P = .005). Triple chemotherapy was also associated with responders. The median overall survival of responders was significantly higher (Blazer 0-1: 42.9 months versus Blazer 2: 20.1 months, P = .018; tumor regression grade 1-3: 42.9 months versus tumor regression grade 4-5: 25.1 months, P = .04). CONCLUSION: A pathologic response to chemotherapy is associated with second-stage completion and longer survival. Further studies are needed to achieve the early identification of patients for whom the benefit of the second surgical stage is less straightforward.
引用
- Quénet F, Pissas MH, Gil H, et al. Two-stage hepatectomy for colorectal liver metastases: Pathologic response to preoperative chemotherapy is associated with second-stage completion and longer survival. Surgery. 2018. PMID: 30449697. doi:10.1016/j.surg.2018.10.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。